The near-patient molecular solutions market is projected to grow from USD 4.1 billion in 2025 to USD 8.9 billion by 2035, at a CAGR of 8.0%. PCR-based will dominate with a 41.6% market share, while infectious diseases testing kits will lead the product type segment with a 48.3% share.